Previous studies in 2009 have shown TET2 mutation to be a favorable independent prognostic factor in myelodysplastic syndrome (MDS), and TET2 mutations were associated with poor outcomes in CMML patients [10]. This evidence concerns the gene TET2 and myelodysplastic syndrome.